Home › NDC Lookup › RxCUI directory › RxCUI 1601654

Atazanavir 300 MG / cobicistat 150 MG Oral Tablet — RxCUI 1601654

RxNorm drug concept · Semantic clinical drug
RxCUI 1601654 Semantic clinical drug · SCD ● Current RxNorm concept 1 FDA product 1 package NDC Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI1601654
Official nameAtazanavir 300 MG / cobicistat 150 MG Oral Tablet
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
FDA products mapped1
Package NDCs mapped1
Reported Medicaid activity (SDUD)1,431 prescriptions · 15 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Atazanavir: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • This is one of the most common things people notice on atazanavir, and it happens to almost everyone who takes it. The medicine causes a buildup of a pigment called bilirubin in yo...
  • Why does my skin and the whites of my eyes look yellow since I started atazanavir?
  • Yes — this one really matters. Taking atazanavir with food can increase the amount your body absorbs by a significant margin, and it also keeps your blood levels more consistent th...
  • Do I really have to take this with food every single time?
📖 Read our full Atazanavir guide →

🕸️ Concept Web — How Atazanavir 300 MG / cobicistat 150 MG Oral Table... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Atazanavir 300 MG / cobicistat 150 MG Oral Tablet RxCUI 1601654

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 3

    The active substance itself — no strength, form, or brand attached yet.

    • Atazanavir 343047
    • Cobicistat 1306284
    • Atazanavir / cobicistat 1601653
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Evotaz 1601655
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Atazanavir / cobicistat Oral Tablet 1601652
    • Atazanavir / cobicistat Oral Product 1601650
    • Atazanavir / cobicistat Pill 1601651
    • Atazanavir / cobicistat Oral Tablet [Evotaz] 1601657
    • Evotaz Oral Product 1601658
    • Evotaz Pill 1601659
    • Oral Tablet 317541
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 4

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 16 of 17 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Atazanavir 300 MG SCDC · 664740
  • Cobicistat 150 MG SCDC · 1306285
  • Atazanavir / cobicistat Oral Tablet SCDF · 1601652
  • Atazanavir / cobicistat Oral Product SCDG · 1601650
  • Atazanavir / cobicistat Pill SCDG · 1601651

Brand-Name Concepts

📦 FDA Products & Package NDCs

1 product · 1 package NDC
1 package NDC map to RxCUI 1601654 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
00003-3641-11 30 TABLET in 1 BOTTLE (0003-3641-11) EVOTAZ E.R. Squibb & Sons, L.L.C. 2015-01-29
Observed labelers: E.R. Squibb & Sons, L.L.C. (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

💲 Pricing (NADAC)

NADAC is CMS's National Average Drug Acquisition Cost — roughly what pharmacies pay to buy the drug. It is an acquisition benchmark, not your copay.
Per ea · median
$51.9820
Range $51.9820–$51.9820 · middle 50% $51.9820–$51.9820 · 1 NDCs
Latest compatible distributions from the CMS NADAC file · dataset watermark 2026-07-10. Prices vary by package and pharmacy; a distribution is shown instead of one misleading number. Rows the dataset is silent on carry no price. No zero-cost conclusion should be drawn.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.